Search research articles
Contact Us
Filters
Showing results (181-190 of 206) with videos related to
Page
of 21
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2024
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study
Akihito Kawazoe, Rui-Hua Xu, Pilar García-Alfonso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 3, 2018
Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110)
Dominik Paul Modest, Ludwig Fischer von Weikersthal, Thomas Decker, et al.
Frontiers in Oncology
|
March 7, 2022
Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial
Annika Kurreck, Volker Heinemann, Ludwig Fischer von Weikersthal, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 23, 2025
Reduced monocytic IL10 expression in PD1 inhibitor-treated patients is a harbinger of severe immune-related adverse events
Stanislav Rosnev, Baldur Sterner, Phillip Schiele, et al.
International Journal of Cancer
|
October 16, 2023
Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212)
Greta Sommerhäuser, Meinolf Karthaus, Annika Kurreck, et al.
Acta Oncologica (Stockholm, Sweden)
|
May 1, 2015
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104
Stephan Kruger, Stefan Boeck, Volker Heinemann, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 13, 2025
Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer
Lena Weiss, Sebastian Stintzing, Arndt Stahler, et al.
Cancers
|
February 15, 2022
Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy
Annabel H S Alig, Volker Heinemann, Michael Geissler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2025
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer
Arndt Stahler, Dominik Paul Modest, Sebastian Stintzing, et al.
International Journal of Cancer
|
December 30, 2016
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306)
Dominik P Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Page
of 21
Search research articles
Search
Showing results (181-190 of 206) with videos related to
Sort By:
Page
of 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2024
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study
Akihito Kawazoe, Rui-Hua Xu, Pilar García-Alfonso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 3, 2018
Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110)
Dominik Paul Modest, Ludwig Fischer von Weikersthal, Thomas Decker, et al.
Frontiers in Oncology
|
March 7, 2022
Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial
Annika Kurreck, Volker Heinemann, Ludwig Fischer von Weikersthal, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 23, 2025
Reduced monocytic IL10 expression in PD1 inhibitor-treated patients is a harbinger of severe immune-related adverse events
Stanislav Rosnev, Baldur Sterner, Phillip Schiele, et al.
International Journal of Cancer
|
October 16, 2023
Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212)
Greta Sommerhäuser, Meinolf Karthaus, Annika Kurreck, et al.
Acta Oncologica (Stockholm, Sweden)
|
May 1, 2015
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104
Stephan Kruger, Stefan Boeck, Volker Heinemann, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 13, 2025
Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer
Lena Weiss, Sebastian Stintzing, Arndt Stahler, et al.
Cancers
|
February 15, 2022
Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy
Annabel H S Alig, Volker Heinemann, Michael Geissler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2025
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer
Arndt Stahler, Dominik Paul Modest, Sebastian Stintzing, et al.
International Journal of Cancer
|
December 30, 2016
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306)
Dominik P Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Page
of 21